ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HCM Hutchmed (china) Limited

267.50
3.00 (1.13%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hutchmed (china) Limited LSE:HCM London Ordinary Share KYG4672N1198 ORD USD0.10
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  3.00 1.13% 267.50 265.00 267.00 273.00 265.50 266.50 18,840 16:35:28
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 838M 100.78M - N/A 0
Hutchmed (china) Limited is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HCM. The last closing price for Hutchmed (china) was 264.50p. Over the last year, Hutchmed (china) shares have traded in a share price range of 173.60p to 338.00p.

Hutchmed (china) currently has 871,256,270 shares in issue.

Hutchmed (china) Share Discussion Threads

Showing 3451 to 3471 of 4100 messages
Chat Pages: Latest  140  139  138  137  136  135  134  133  132  131  130  129  Older
DateSubjectAuthorDiscuss
23/8/2021
02:28
Being received quite well in HK at present (+3.5%):

Hong Kong, Shanghai & Florham Park, NJ — Monday, August 23, 2021: HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that HUTCHMED has been selected as a constituent stock of several indexes administered by Hang Seng Indexes Company Limited (“Hang Seng”), including the Hang Seng Composite Index, in accordance with the latest index series release by Hang Seng, with effect from Monday, September 6, 2021.

lauders
20/8/2021
10:14
Yup. I've got a small stake in Tencent as well 😕.
nahoon
20/8/2021
08:51
The likes of Alibaba have halved in the year and are now back to levels not seen since Aug 2019.There is little sign of the Chinese authorities loosening their administrative grip in the field of retail,tech and finance.Some fund managers regard the fall in the Chinese exchanges as a buying opportunity but others have sold out not being prepared to guess the likely machinations of the Chinese political masters.Long term its probably right to maintain a Chinese weighting in a global portfolio but its very irritating to see the slump in stock prices purely due to political interference whether that interference is justified or not.I feel that the fall back in HCM is almost entirely due to shifts of global capital out of Chinese exchanges and its difficult to see confidence returning soon.There's a health warning attached to buying all chinese related securities just now.
steeplejack
20/8/2021
07:41
I'm guessing it's just caught up in the worries over the Chinese government's crackdown on listed companies.

But on the upside, this is from today's FT: "BlackRock’s research unit has said China should no longer be considered an emerging market and recommended investors boost their exposure to the country by as much as three times."

Patience...

nahoon
20/8/2021
07:37
Morning All8.8% drop this am in HK. Has anyone got insight, is it profit taking after recent launch, worries over tension between Ch and USA, non shares news? I had a look over the usuals and nothing to be seen.
chester9
14/8/2021
03:57
Two links courtesy of "tacly" over on the LSE BB:

Hutchmed (HCM US)
Building momentum towards a fully-fledged biopharma

■ Hutchmed (HCM) is a China-based biopharma company with an
proven in-house innovative pipeline focusing on oncology
■ HCM extends its global commercial footprint, paving the way for
internal pipeline monetization and external BD opportunities
■ We initiated coverage on HCM with a BUY rating and FY22E
SOTP-based TP of USD54.6, implying 28% upside potential

+



We know the future is bright. These two help reinforce that viewpoint.

lauders
11/8/2021
06:27
Trinity Delta have issued a new brief update note:-
nerdofsteel
10/8/2021
16:52
Evaluate's World Preview 2021 Outlook to 2026 has been published today and there's a specific section on China (P10)
nerdofsteel
10/8/2021
09:08
Getting some nice coverage in the trade press on the Epizyme deal
nerdofsteel
10/8/2021
08:01
And sense a break of 650p is getting closer and closer. After many years price momentum seems to be building.
its the oxman
10/8/2021
06:07
HUTCHMED is uniquely positioned to make the most of TAZVERIK®
Summary rationale
*ES = epithelioid sarcoma, a solid tumor; FL = follicular lymphoma, a hematological malignancy –a subtype of non-Hodgkin’s lymphoma.

Global First-in-Class Product

First and only US FDA approved EZH2 inhibitor
1stapprovals in Jan & Jun 2020, for ES & FL*

Accelerates China Hematology Commercialization

Advances build-out of hematology sales team–ahead of potential launches of 5 clinical assets

Manufacturing expertise & capabilities–substantial and growing infrastructure
Pipeline Synergy

Broad PotentialApplicability

Inhibit epigenetics inhibit cell proliferation–EZH2 allows transcription of genes involved in cell functions such as cell cycle control and terminal differentiation
Highly favorable safety profile–potential combos across HUTCHMED portfolio

This is a very good stategic play for Hutchmed. We have to hope Epizyme's viability continues, which it should as U.S. sales really start to take off this year.

nerdofsteel
09/8/2021
14:35
NofS - Have you changed your name here to yidarmyTom? LSE postings would tend to support this conclusion.

Good meeting just completed. Looks like this is a specific product that HCM are interested in and for now the net is not being cast for more like it just now. Opportunity and the great safety profile of TAZVERIK® made it a worthy candidate. Look forward to more developments as they come.

lauders
09/8/2021
09:58
I think today's deal on TAZVERIK® gives Hutchmed a great opportunity top leverage its sales teams and other infrastructure in China to market drugs owned by Companies who want to partner and who have no resoyrce in region, or cannot navigate the Chinese Regulatory system. Beigene have made a great success of it. TAZVERIK® is forecast to exceed $900m pa peak sales in the U.S. so it could approach that in what is a larger chinese market, even with NRDL discounts.

I'm looking forward to the Company's view on forecast peak sales on the conference call today.

I can seem more of these licencing deals coming our way.

I also look froward to increased revenue forecasts from Analysts.

yidarmytom
09/8/2021
07:53
Shares up a tad so guess it's perceived as a positive.
its the oxman
09/8/2021
01:10
An RNS to come today from the looks of things:

HUTCHMED and Epizyme Announce Strategic Collaboration to Develop and Commercialize TAZVERIK® (tazemetostat) in Greater China

– Collaboration designed to accelerate global development and investigate TAZVERIK® combinations with HUTCHMED’s novel oncology medicines portfolio –

– Epizyme to receive US$25 million upfront payment and up to US$285 million in potential milestone payments, together with additional tiered royalties; HUTCHMED to receive development and commercial rights to TAZVERIK® in Greater China –

– HUTCHMED to host a webcast and call on Monday, August 9, at 9:30 a.m. EDT / 2:30 p.m. BST / 9:30 p.m. HKT – see www.hutch-med.com/event for details –

lauders
02/8/2021
09:51
Nahoon, agree

US talking it’s own book hard in my opinion.

China moves to regulate tech business, Bitcoin etc and it’s called everything from government manipulation to a covert strike against the western world .

US moves to regulate Tech business, Bitcoin etc and it’s applauded as much over due necessity. Blatantly holds up approval of Astrazenica COVID vaccine whilst it’s own pharmas price gouge its own people and now the rest of the world and so forth.

Business as usual then..

dbadvn
02/8/2021
08:15
I feel we're doing exceptionally well considering all the anti-Chinese sentiment around at the moment.
nahoon
01/8/2021
19:22
explain the relevance to Hutchmed please, Thank You
nerdofsteel
31/7/2021
03:21
Nice short interview here by CH:



Innovative drugs are safe(r) from Chinese regulation and "interference" than generic.

lauders
31/7/2021
01:11
So much for global markets!

More like "So much for efficient markets!" LOL

Will be nice to see HCM over 700p one of these coming days.

lauders
29/7/2021
20:25
That’s a very sad sjack.

Usd close at near as 41usd, hk at almost 50usd. More than 20% difference.

So much for global markets!

dbadvn
Chat Pages: Latest  140  139  138  137  136  135  134  133  132  131  130  129  Older

Your Recent History

Delayed Upgrade Clock